Profusa, Inc. (PFSA): Entry into a Material Definitive Agreement

Profusa, Inc. (PFSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. The information set forth under Item 2.03 below is hereby incorporated herein by reference. Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Note Mo

Original reporting
Published Nov 6, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$PFSA
Neutral
high confidence
Mentioned
$PFSA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PFSANeutralMed
01

Why it matters

The amendment provides a protective floor price, which may be interpreted as a defensive move to stabilize the share price amid ongoing financing activities.

02

Market read

The filing is a primary disclosure of a material agreement amendment that could affect PFSA's share price and dilution profile.

03

What to watch

Potential future conversions at the floor price could still dilute existing shareholders if large amounts are converted.

Relevance 6/10Novelty 7/10Timing: effective immediately after filing on Nov 6 2026

Background

Profusa Inc. (PFSA) is a biotech firm that previously issued a $2.5 M promissory note convertible into common stock. The latest amendment revises conversion terms.

Company-level read

Ticker impact

$PFSANeutralHigh confidence
Context

Profusa filed an 8‑K reporting Amendment No. 4 to its Note Modification and Conversion Agreement, changing the conversion price floor to $0.20 and adjusting terms for future conversions.

Expected impact

potential modest upside as the floor price may support the share price, but limited upside if conversion pressure remains low

Evidence & confidence

The new floor price reduces downside risk for shareholders and may be viewed positively by the market.

Market effects

Minimal; primarily affects micro‑cap biotech financing practices.

None beyond the company's own share price.

Low; the filing is company‑specific.

Counterpoint

If the conversion floor is seen as too low, investors may doubt future financing flexibility.

Key entities

  • Profusa, Inc.

    Issuer of the convertible note and subject of the 8‑K filing.

  • NorthView Sponsor I LLC

    Holder of the convertible note.

Related articles

$PFSALow

Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company

Profusa, Inc. (PFSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of w

$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

$PFSAMedAI 8/10

PFSA Stock Falls 19% Amid Diagnostics Acquisition News

Profusa (PFSA) said it signed a non-binding term sheet to acquire a privately held commercial diagnostics and toxicology testing company. The target estimates 2025 net revenues of about $111 million. Profusa would issue shares equal to 19.99% plus non-voting convertible preferred stock, subject to approval, and expects about $7 million financing via convertible notes. PFSA shares fell sharply after the news.